Department of Systems Biology, Institute for Personalized Cancer Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX 77054, USA.
Mol Oncol. 2012 Apr;6(2):147-54. doi: 10.1016/j.molonc.2012.01.008. Epub 2012 Feb 17.
Delivering personalized therapeutic options to cancer patients based on the genetic and molecular aberrations of the tumor offers great promise to improve the outcomes of cancer therapy. Significant progress in biotechnology has allowed the measurement of tens of thousands of "omic" data points across multiple levels (DNA, RNA protein, metabolomics) from a single tumor biopsy sample in a reasonable time frame for making clinical decisions. With this data in hand, the challenge from the bioinformatics and systems biology point of view is how does one convert data into information and knowledge that can improve the delivery of personalized therapy to the patient.
基于肿瘤的遗传和分子异常为癌症患者提供个性化的治疗选择，有望改善癌症治疗的效果。生物技术的重大进展使得在合理的临床决策时间内，能够从单个肿瘤活检样本中测量数千个“组学”数据点，涵盖多个层面（DNA、RNA、蛋白质、代谢组学）。有了这些数据，从生物信息学和系统生物学的角度来看，挑战在于如何将数据转化为信息和知识，从而改善个性化治疗方案向患者的传递。
